Related Experiment Video

Updated: Jun 7, 2026

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
15:48

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

Marfan syndrome: clinical manifestations, pathophysiology and new outlook on drug therapy

Ana Lebreiro1, Elisabete Martins, Cristina Cruz

  • 1Serviços de Cardiologia do Hospital de S. João, Porto, Portugal. ana.lebreiro@gmail.com

Revista Portuguesa De Cardiologia : Orgao Oficial Da Sociedade Portuguesa De Cardiologia = Portuguese Journal of Cardiology : an Official Journal of the Portuguese Society of Cardiology
|October 23, 2010
PubMed

Insights

Marfan Syndrome (MFS) is a genetic connective tissue disorder linked to FBN1 gene mutations. Losartan offers a therapeutic avenue by targeting TGF-beta pathways, improving patient management.

Area of Science:

  • Genetics
  • Molecular Biology
  • Pathophysiology

Background:

  • Marfan Syndrome (MFS) is a genetic connective tissue disorder affecting skeletal, cardiovascular, and ocular systems.
  • It is primarily caused by mutations in the fibrillin-1 (FBN1) gene, an extracellular matrix protein.
  • Diagnosis relies on established clinical criteria, such as the Ghent criteria.

Purpose of the Study:

  • To elucidate the pathophysiologic mechanisms underlying Marfan Syndrome.
  • To explore the role of transforming growth factor-beta (TGF-beta) signaling pathways in MFS.
  • To identify novel therapeutic strategies for Marfan Syndrome.

Main Methods:

  • Utilized animal models to investigate MFS pathophysiology.
  • Analyzed the impact of FBN1 mutations on TGF-beta signaling.
  • Evaluated therapeutic interventions targeting TGF-beta pathways.

Main Results:

  • Animal studies revealed the central role of TGF-beta signaling in MFS pathogenesis.
  • Identified losartan as a potential therapeutic agent due to its TGF-beta antagonistic effects.
  • Highlighted the need for ongoing patient monitoring due to expected new manifestations in an aging population.

Conclusions:

  • FBN1 mutations in Marfan Syndrome significantly impact TGF-beta signaling.
  • Targeting TGF-beta pathways, for example with losartan, presents a promising therapeutic strategy.
  • Continuous monitoring is essential for managing evolving clinical manifestations in aging MFS patients.

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications